

Docket No: 17923-002001

RECORDATION FORM COVER SHEET TRADEMARKS ONLY

Commissioner for Trademarks: Please record the attached copies of an original document.

1. Name of conveying party(ies):
Cengent Therapeutics, Inc.

Individual(s)
 Association
 General Partnership
 Limited Partnership
 Corporation—State California
 Other _____

Additional name(s) attached? Yes No

2. Name and address of receiving party(ies):
Perseus-Soros Biopharmaceutical Fund, LP
888 Seventh Avenue, 29th Floor
New York, NY 10106

Individual(s) Citizenship _____
 Association _____
 General Partnership _____
 Limited Partnership Delaware
 Corporation—State _____
 Other _____

3. Nature of conveyance:

Assignment
 Merger
 Security Agreement
 Change of Name
 Other:

Execution Date: **October 29, 2004**

If the assignee is not domiciled in the United States, a domestic representative designation is attached. Yes No

Additional names/addresses attached? Yes No

4. Application number(s) or trademark number(s):

A. Trademark Application No(s):
75/226,837

B: Trademark No(s):

2,307,950 2,534,211 2,657,472
2,368,701 2,565,457 2,703,293
2,416,059 2,594,536 2,705,142
2,423,602 2,640,309 2,716,849

Additional numbers attached? Yes No

5. Name/address of party to whom correspondence concerning document should be mailed:

Dale L. Rieger
Fish & Richardson P.C.
12390 El Camino Real
San Diego, CA 92130

6. Total number of applications and registrations involved: **13**

7. Total fee (37 CFR §3.41): **\$ 520.00**


Enclosed
 Authorized to charge Deposit Account.

8. Deposit Account No.: **06-1050**

Please apply any additionally charges, or any credits, to our Deposit Account No. 06-1050.

DO NOT USE THIS SPACE

9. Statement and Signature: *To the best of my knowledge and belief, the foregoing information is true and correct and the attached is a true copy of the original document.*

Dale L. Rieger  **1/26/05**

Name of Person Signing Signature Date


Total number of pages including cover sheet, attachments, and document: 13

50258335.doc

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

Date of Transmission January 28, 2005


Diana Bradley

TRADEMARK


CH \$340.00 06-1050 75226837

01/13/2005
700145767

Docket No: 17923-002001

RECORDATION FORM COVER SHEET
TRADEMARKS ONLY

Commissioner for Trademarks: Please record the attached copies of an original document.

1. Name of conveying party(ies): Cengent Therapeutics, Inc. <input type="checkbox"/> Individual(s) <input type="checkbox"/> Association <input type="checkbox"/> General Partnership <input type="checkbox"/> Limited Partnership <input checked="" type="checkbox"/> Corporation—State <u>California</u> <input type="checkbox"/> Other _____ Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies): Perseus-Soros Biopharmaceutical Fund, LP 888 Seventh Avenue, 29th Floor New York, NY 10106 <input type="checkbox"/> Individual(s) Citizenship _____ <input type="checkbox"/> Association _____ <input type="checkbox"/> General Partnership _____ <input checked="" type="checkbox"/> Limited Partnership <u>Delaware</u> <input type="checkbox"/> Corporation—State _____ <input type="checkbox"/> Other _____ If the assignee is not domiciled in the United States, a domestic representative designation is attached. <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Additional name(s)/address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input checked="" type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: Execution Date: <u>October 20, 2004</u>			
4. Application number(s) or trademark number(s): A. Trademark Application No(s): <u>757226,837</u> B. Trademark No(s): <u>2,307,950 2,534,211 2,657,472</u> <u>2,368,701 2,565,457 2,703,293</u> <u>2,416,059 2,594,536 2,705,142</u> <u>2,423,602 2,540,309 2,716,849</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name/address of party to whom correspondence concerning document should be mailed: PTO Customer Number 20985		6. Total number of applications and registrations involved: 13 7. Total fee (37 CFR §3.41): \$ 520.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to charge Deposit Account 8. Deposit Account No.: <u>08-1050</u> Please apply any additional charges, or any credits, to our Deposit Account No. 08-1050.	
DO NOT USE THIS SPACE			
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and the attached is a true copy of the original document.</i> <div style="display: flex; justify-content: space-between; align-items: flex-end;"> <div style="width: 20%;"> <u>Dale L. Rieger</u> <small>Name of Person Signing</small> </div> <div style="width: 40%; text-align: center;">  <small>Signature</small> </div> <div style="width: 20%; text-align: right;"> <u>1/13/05</u> <small>Date</small> </div> </div>			
Total number of pages including cover sheet, attachments, and document: 13			

50256214.doc

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

Date of Transmission: January 13, 2005
Liana Bradley
Liana Bradley

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, modified or supplemented from time to time, this "Agreement"), dated as of October 29, 2004, is made by and among Cengent Therapeutics, Inc., a California corporation (together with its successors and assigns, the "*Company*" or the "*Borrower*"), and Pegasus-Soros BioPharmaceutical Fund, LP, in its capacity as representative and collateral agent for and on behalf of the Lenders (in such capacity, the "*Collateral Agent*" or the "*Secured Party*").

WHEREAS, the Company and, among others, the Collateral Agent are party to that certain Note and Warrant Purchase Agreement, dated as of October 29, 2004 (as amended, modified or supplemented from time to time, the "*Purchase Agreement*").

WHEREAS, pursuant to the Purchase Agreement certain lenders (the "*Lenders*") have or may in the future make loans to the Company, as evidenced by certain senior secured convertible promissory notes (the "*Notes*") issued pursuant to the Purchase Agreement.

WHEREAS, pursuant to the terms of the Purchase Agreement, the Collateral Agent has been appointed by the Lenders as their representative and collateral agent for the purpose, among other things, of entering into this Agreement for the benefit of the Lenders and holding the security interests created hereby.

WHEREAS, it is a condition precedent to the obligations of Lenders pursuant to the Purchase Agreement that the Company execute and deliver this Agreement for filing by the Collateral Agent with the United States Patent and Trademark Office (the "*PTO*") and United States Copyright Office (the "*Copyright Office*") (and any other relevant recording systems in any domestic or foreign jurisdiction) as further evidence of and to effectuate such grant of a security interest in the intellectual property rights of the Company.

Accordingly, the Company and the Collateral Agent hereby agree as follows:

1. Definitions; Interpretation. All capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings assigned to them pursuant to the Purchase Agreement.

2. Grant of Security Interest. As a continuing security for the payment and performance of the Obligations (as defined in the Purchase Agreement), the Company hereby grants to the Collateral Agent, for itself and on behalf of and for the ratable benefit of each of the Lenders, a security interest in and to all of the Company's rights, title and interests in, to and under the following property, whether now existing or owned or hereafter acquired, developed or arising (collectively, the "*Intellectual Property Collateral*"):

(a) all intellectual property rights of any nature or character including, without limitation, and whether domestic or foreign: (A) all patents and patent applications, all licenses in respect to any rights identified in this clause (a)(A) and all income and royalties with respect to any licenses, all rights to sue for past, present or future infringement of any of the rights identified in this clause (a)(A), all rights arising from any of the rights identified in this clause

(a)(A) and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part of any of the foregoing; (B) all copyrights and applications for copyright, together with the underlying works of authorship (including titles), whether or not the underlying works of authorship have been published and whether said copyrights are statutory or arise under the common law, and whether registered or unregistered, and all other rights and works of authorship, all rights, claims and demands in any way relating to any such copyrights or works, including royalties and rights to sue for past, present or future infringement, and all rights of renewal and extension of copyright, and all licenses in respect of any of the rights identified in this clause (a)(B) and all income and royalties with respect to any such licenses; (C) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the rights identified in this clause (a)(C) and all income and royalties with respect to any licenses, whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof; (D) all regulatory approvals, consents, permits, licenses and applications in respect of any of the foregoing and all supporting documentation, books and records relating to any of the foregoing; and (E) all trade secrets, trade dress, trade styles, logos, other source or business identifiers, mask-works, mask-work registrations, mask-work applications, software, confidential information, the benefit of confidentiality agreements or non-disclosure agreements, customer lists, license rights (whether or not in respect of any of the rights identified in this clause (a)), advertising materials, operating manuals, methods, processes, know-how, algorithms, formulae, databases, quality control procedures, product, service and technical specifications, operating, production and quality control manuals, sales literature, drawings, specifications, blueprints, descriptions, inventions, name plates and catalogs (the foregoing rights and interests collectively, the "*Intellectual Property Rights*") and including, without limitation, those Intellectual Property Rights listed, from time to time, on the Exhibits to this Agreement;

(b) the entire goodwill of or associated with the businesses now or hereafter conducted by the Company connected with and symbolized by any of the aforementioned properties and assets;

(c) all general intangibles and all intangible Intellectual or other similar property of the Company of any kind or nature and not otherwise described above; and

(d) all products, proceeds and supporting obligations at any time of any and all of the foregoing, including products of products and proceeds of proceeds.

Exhibit A to this Agreement sets forth a list of all of the Company's patents and patent applications; Exhibit B to this Agreement sets forth a list of all of the Company's registered trademarks; Exhibit C sets forth a list of all of the Company's trademark applications; and Exhibit D sets forth a list of all of the Company's registered mask works.

3. **Future Rights.** If and when the Company shall obtain rights to any new Intellectual Property Rights, or obtain rights or benefits with respect to any reissue, division, continuation, renewal, extension or continuation-in-part of any Intellectual Property Rights, or any improvement of any Intellectual Property Rights, which Intellectual Property Rights if

existing at the date hereof would be within the scope of Section 2, the provisions of Section 2 shall automatically apply thereto. The Company shall give to the Collateral Agent prompt notice of the benefit of any registrations or applications the Company may make or obtain to register any Intellectual Property Rights and the Company shall give to the Collateral Agent at the beginning of each calendar quarter a report on any changes or addition to its Intellectual Property Rights. The Company shall do all things deemed necessary or advisable by the Collateral Agent to ensure the validity, perfection, priority and enforceability of the security interests of the Collateral Agent in such future acquired Intellectual Property Collateral. The Company hereby authorizes the Collateral Agent, as its attorney in fact (with power of substitution), to modify, amend, or supplement the Exhibits hereto and to reexecute this Agreement from time to time on Company's behalf and as its attorney-in-fact to include any such future Intellectual Property Collateral and to cause such reexecuted Agreement or such modified, amended or supplemented Exhibits to be filed with the PTO or Copyright Office as applicable.

4. Collateral Agent's Duties. Notwithstanding any provision contained in this Agreement, the Collateral Agent shall have no duty to exercise any of the rights, privileges or powers afforded to it and shall not be responsible to the Company or any other Person for any failure to do so or delay in doing so. Except for the accounting for moneys actually received by the Collateral Agent hereunder or in connection herewith, the Collateral Agent shall have no duty or liability to exercise or preserve any rights, privileges or powers pertaining to the Intellectual Property Collateral.

5. Collateral Agent's Rights and Remedies. The Collateral Agent shall have all rights and remedies available to it under this Agreement, the Purchase Agreement, each other Transaction Document and applicable law with respect to the security interests in any of the Intellectual Property Collateral. The Company agrees that such rights and remedies include, but are not limited to, the right of the Collateral Agent as a secured party to sell or otherwise dispose of the Intellectual Property Collateral pursuant to the UCC.

6. Termination. Upon the indefeasible payment in full in cash of the Notes or the conversion in full of the Notes into Next Equity Securities (as defined in the Purchase Agreement) and performance in full of the Obligations under the Notes and the other Transaction Documents (other than Obligations arising, or to be performed, under the Warrants after such termination), the security interests created by this Agreement shall terminate and the Collateral Agent shall promptly execute and deliver to the Company (at Company's expense) such documents and instruments reasonably requested by the Company as shall be necessary to evidence termination of all such security interests given by the Company to the Collateral Agent hereunder, including cancellation of this Agreement by written notice from the Collateral Agent to the PTO and/or the Copyright Office.

7. Purchase Agreement Provisions. The provisions of Sections 3.5, 12.1 through 12.14 and 12.16 of the Purchase Agreement are incorporated herein by reference and shall be applied as if references to the "Collateral" and "Agreement" therein were references to the "Intellectual Property Collateral" and this "Agreement," respectively. The Company acknowledges that the rights and remedies of the Collateral Agent with respect to the security interests in the Intellectual Property Collateral granted hereby are more fully set forth in the Purchase Agreement and that such rights and remedies are cumulative.


8. Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date first above written.

Company / Borrower:

CENGEN THERAPEUTICS, INC.,
a California corporation

By: 
J. Gordon Foulkes, President

Address: 10929 Technology Place
San Diego, CA 92127

Collateral Agent / Secured Party:

Pereus-Serms BioPharmaceutical Fund, LP,
in its capacity as representative and
collateral agent for the Lenders

By: _____

Name: _____

Title: _____

Address: _____

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

Oct-21-04 00:36 pm From=PERSEUS/SOROS +1212 T-026 P-017/011 F-001

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date first above written.

Company / Borrower:

GENENT THERAPEUTICS, INC.,
a California corporation

By: _____
Name: _____
Title: _____

Address: 10529 Technology Place
San Diego, CA 92127

Collateral Agent / Secured Party:

**PERSEUS-SOROS BIOPHARMACEUTICAL
FUND, LP,**
in its capacity as representative and collateral
agent for the Lenders

By: John F. Brown
Name: John F. Brown
Title: Attorney-in-Fact

Address: _____

[SIGNATURE PAGE TO INTELLECTUAL PROPERTY SECURITY AGREEMENT]

EXHIBIT A

Patents (or Patent Applications) of Company

Country	Status	Application/Patent No.	Filing Date	Title
US	Abandoned	09/272,814	3/19/99	Interface to Database for Molecular Visualization and Analysis of Molecular Structures
US	Abandoned	09/531,995 (CIP)	3/20/00	Interface to Database for Molecular Visualization and Analysis of Molecular Structures
PC	Completed	PCT/US00/1474	3/20/00 (issued 9/28/00)	Interface to Database for Molecular Visualization and Analysis of Molecular Structures
Europe	Abandoned	00918205.6	3/20/00	Interface to Database for Molecular Visualization and Analysis of Molecular Structures
Japan	Abandoned	2000-607115	3/20/00	Interface to Database for Molecular Visualization and Analysis of Molecular Structures
US	Abandoned	09/438,566	11/10/99	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US	Abandoned	09/704,362	11/01/00	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US	Abandoned	09/709,905	11/10/00	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US	Pending - response due 01/05/04	10/271,181	10/10/02	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US	CON of 09/704,362	10/911,846	8/04/04	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
Europe	Abandoned	00980321.4	11/10/00	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
PC	Complete	PCT/US00/30863	11/10/00 (granted 5/17/01)	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US	CON OF 09/709,905	10/923,620	8/19/04	Use of Computationally Derived Protein Structures of Genetic Polymorphisms in Pharmacogenomics for Drug Design and Clinical Applications
US		60/271,202	2/23/01	Kits Containing Reagents and 3-Dimensional Protein Structural Information, and Methods of Use Thereof
US	Abandoned	10/084,794	2/25/02	Kits Containing Reagents and 3-Dimensional Protein Structural Information, and Methods of Use Thereof
US	Abandoned	60/286,226	4/26/01	Electronic Search Method for Secure Searching of Bioinformatics Data
US	Expired	60/287,593	5/01/01	Method Of Diagnosing Inapparent Diseases From Common Clinical Tests Using A Bayesian Analysis To Mine For Hidden Patterns In A Database Via Data Fusion And Integration
US	Abandoned	10/138,068	5/01/02	Method Of Diagnosing Inapparent Diseases From Common Clinical Tests Using A Bayesian Analysis To Mine For Hidden Patterns In A Database Via Data Fusion And Integration
PC	Abandoned	PCT/US02/14133	5/01/01	Method Of Diagnosing Inapparent Diseases From Common Clinical Tests Using A Bayesian Analysis To Mine For Hidden Patterns In A Database Via Data Fusion And Integration

A-1

10428343.DOC

Country	Status	Application/ Patent No.	Filing Date	Title
US	Expired	60/360,109	2/25/02	Generation and Comparison of Sequence-Based Structure Plots Derived from Analysis of 3-D Molecular Structures
US	Expired	60/360,126	2/25/02	Generation and Use of Surface Structural Difference Maps of Molecules
US	Expired	60/370,101	4/02/02	Biological Structure Mining and Activity Recognition for Use in 3D Structure and Function Similarity Searching Among Proteins
US	Expired	60/366,461	3/19/02	Discrete Bayesian Analysis of Data
US	Office Action	10/294,328	3/19/03	Discrete Bayesian Analysis of Data
PC	Abandon	PCT/US03/08959	3/19/03	Discrete Bayesian Analysis of Data
US	Abandon	10/649,111	8/26/03	Discrete Bayesian Analysis of Data
US	-	60/329,937	10/16/01	Organosulfur Inhibitors of Tyrosine Phosphatases
US	Awaiting First Examination	10/493,113	4/15/04	Organosulfur Inhibitors of Tyrosine Phosphatases
PCT	National Stage Entered	PCT/US02/33076	10/16/02	Organosulfur Inhibitors of Tyrosine Phosphatases
Canada	Awaiting First Examination	2,463,724	10/16/02	Organosulfur Inhibitors of Tyrosine Phosphatases
Australia	Awaiting First Examination	2002347912	10/16/02	Organosulfur Inhibitors of Tyrosine Phosphatases
Europe	Awaiting First Examination	02784123.8	10/16/02	Organosulfur Inhibitors of Tyrosine Phosphatases
Japan	Awaiting First Examination	2003-535722	10/16/02	Organosulfur Inhibitors of Tyrosine Phosphatases
US	Pending	60/587,023	7/9/04	Oxygen/Nitrogen Heterocycle Inhibitors of Tyrosine Phosphatases
US	Pending	60/634,450	12/8/04	Oxygen/Nitrogen Heterocycle Inhibitors of Tyrosine Phosphatases
US	Pending	N/A	12/22/04	Oxygen/Nitrogen Heterocycle Inhibitors of Tyrosine Phosphatases
US	Pending	60/581,251	6/17/04	Trisubstituted Nitrogen Modulators of Tyrosine Phosphatase
US	Pending	60/634,200	12/7/04	Trisubstituted Nitrogen Modulators of Tyrosine Phosphatase
US	Pending	N/A	12/22/04	Trisubstituted Nitrogen Modulators of Tyrosine Phosphatase
US	Pending	60/607,034	9/2/04	Thiazole and Thiazazole Inhibitors of Tyrosine Phosphatase
US	Pending	N/A	12/22/04	Thiazole and Thiazazole Inhibitors of Tyrosine Phosphatase

Licenses of Patents and Patent Applications:

Country	Application/ Patent No.	Filing Date	Title
United States	60/087,110	5/27/98	Fold And Function Prediction By A Hierarchy Of Threading And Modeling Methods
WIPO	US99/11911	5/27/99	Fold And Function Prediction By A Hierarchy Of Threading And Modeling Methods
United States	60/117,570	1/21/99	Tools For Generalized Homology Modeling
United States	60/099,300	8/25/98	Mutation Analysis
United States	09/493,022	1/27/00	Method For Prediction Of Protein Function And Functional Analysis Using The Sequence-To-Structure-To-Function Paradigm
United States			Protein Modeling Tools

Country	Application/ Patent No.	Filing Date	Title
Canada	2359889	1/27/00	Protein Modeling Tools
Europe	00910004.1	1/27/00	Protein Modeling Tools
Hong Kong	00910004.1	1/27/00	Protein Modeling Tools
Japan	2000-598522	1/27/00	Protein Modeling Tools
WIPO	US00/02118	1/27/00	Protein Modeling Tools
United States	09/562,488	10/17/01	Protein Modeling Tools
United States	60/118,842	2/5/99	Site Match: A Pattern Matching Program To Analyze Conservation Of Functional Features In Predicted Protein Structures
United States	09/322,067	5/27/99	Methods And Systems For Predicting Protein Function
Australia	4218799	5/27/99	Methods And Systems For Predicting Protein Function
Canada	2,340,284	5/27/99	Methods And Systems For Predicting Protein Function
China	99812531.8	5/27/99	Methods And Systems For Predicting Protein Function
Europe	99926014.4	5/27/1999	Methods And Systems For Predicting Protein Function
India	US99/11913	5/27/99	Methods And Systems For Predicting Protein Function
Israel	141510	2/19/01	Methods And Systems For Predicting Protein Function
Japan	2000-565498	5/27/99	Methods And Systems For Predicting Protein Function
New Zealand	516235	5/27/99 (issued 5/10/04)	Methods And Systems For Predicting Protein Function
Russian Federation	2000/107828	5/27/99	Methods And Systems For Predicting Protein Function
WIPO	US99/11913	5/27/99	Methods And Systems For Predicting Protein Function
United States	09/339,821	4/20/01 (issued as 6,631,332 on 10/7/03)	Methods And Systems For Predicting Protein Function
United States	Closed		Method For Prediction Of Protein Function And Functional Analysis Using The Sequence-To-Structure-To-Function Paradigm

EXHIBIT B
Trademarks of Company

Registration No.	Registration Date	Filing Date	Registered Owner	Mark	Country of Origin
2,416,059	12/26/00	03/06/97	Structural Bioinformatics, Inc.	CombiLib	US
4375986	04/14/00	04/09/98	Structural Bioinformatics, Inc.	CombiLib	JAPAN
2,640,309	10/22/02	02/28/00	Structural Bioinformatics, Inc.	DynaPharm	US
4349382	01/07/00	04/09/98	Structural Bioinformatics, Inc.	DynaPharm	JAPAN
495698	06/07/99	03/05/97	Squawal Bioinformatics, Inc.	DynaPharm	EUROPE
2,368,701	07/18/00	09/02/99	Structural Bioinformatics, Inc.	Genes to Leads	US
608604	01/04/00	08/05/97	Structural Bioinformatics, Inc.	Genes to Leads	EUROPE
2,565,457	04/30/02	10/17/97	Structural Bioinformatics, Inc.	GeneWeb	US
2,705,142	04/08/03	09/14/00	Structural Bioinformatics, Inc.	ProMax	US
2,716,849	03/20/03	09/04/97	Structural Bioinformatics, Inc.	SBdBase	US
2,657,472	12/10/02	09/06/96	Structural Bioinformatics, Inc.	SBdBase	US
4397003	07/07/00	04/09/98	Structural Bioinformatics, Inc.	SBdBase	JAPAN
2,307,950	01/11/00	04/28/98	Structural Bioinformatics, Inc.	SVdBase	US
833929	12/16/99	06/12/98	Structural Bioinformatics, Inc.	SVdBase	EUROPE
2,594,536	07/16/02	12/01/97	Structural Bioinformatics, Inc.	SBI & Design	US
2,423,602	01/23/01	08/12/96	Structural Bioinformatics, Inc.	Structural Bioinformatics, Inc.	US
2,534,211	01/29/02	06/11/01	Structural Bioinformatics, Inc.	Structural Insight	US
2,703,293	04/01/03	11/06/00	Structural Bioinformatics, Inc.	StructureBank	US

EXHIBIT C

Pending Trademark Applications of Company

<u>Application No.</u>	<u>Filing Date</u>	<u>Applicant</u>	<u>Mark</u>	<u>Country of Filing</u>
2000-018363	02/29/00	Structural Bioinformatics, Inc.	SDBase (Divisional)	JAPAN
75/226,837	01/15/97	Structural Bioinformatics, Inc.	SBI (Stylized)	US
000568541	07/15/97	Structural Bioinformatics, Inc.	SBI (Stylized)	EUROPE
000456756	01/21/97	Structural Bioinformatics, Inc.	Structural Bioinformatics, Inc.	EUROPE

EXHIBIT D

Copyright/Mask-PCT Authority Registrations of Company

<u>Copyright/Mask PCT Authority</u> <u>Name</u>	<u>Reg. No.</u>	<u>Date of Issue</u>	<u>Country of Filing</u>

D-1

10428394.J.DOC